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Abstract. Amyloid formation of the synaptic brain protein α-synuclein (αS) is related to degeneration of dopaminergic neurons in
Parkinson’s disease patients. αS is thought to function in vesicle transport and fusion and it binds strongly to negatively charged vesicles
in vitro. Here we combined circular dichroism, ﬂuorescence and imaging methods in vitro to characterize the interaction of αS with
negatively charged vesicles of DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine, sodium salt) and DOPG (1,2-dioleoyl-sn-glycero-3-
phospho-(1′-rac-glycerol), sodium salt) and the consequences of such interactions on αS amyloid formation. We found that lipid head-
group chemistry modulates αS interactions and also aﬀects amyloid ﬁber formation. During the course of the experiments, we made
the unexpected discovery that pre-formed αS oligomers, typically present in a small amount in the αS starting material, acted as templates
for linear growth of anomalous amyloid ﬁbers in the presence of vesicles. At the same time, the remaining αS monomers were restricted
from vesicle-mediated nucleation of amyloid ﬁbers. Although not a dominant process in bulk experiments, this hidden αS aggregation
pathway may be of importance in vivo.
1. Introduction
The protein alpha-synuclein (αS) is a major component of
amyloid aggregates found in Lewy body inclusions, which
are the pathological hallmark of Parkinson’s disease (PD).
PD is the second most common neurological disorder and
the most common movement disorder. The assembly pro-
cess of the 140-residue protein αS into amyloid ﬁbrils, via
oligomeric intermediates, has been linked to the molecular
basis of PD (Uversky, 2007). Duplications, triplications
and point-mutations in the αS gene are related to familial
PD cases (Polymeropoulos et al. 1997; Spillantini et al.
1997).
The exact function of αS is unknown, but it is suggested that
the protein is involved in synaptic vesicle release and traf-
ﬁcking, regulation of enzymes and transporters, and control
of the neuronal apoptotic response (Dev et al. 2003; Lassen
et al. 2016). αS is present at presynaptic nerve terminals
(Eliezer et al. 2001; Iwai et al. 1995; Maroteaux et al.
1988) and it is reported that the protein exists in vivo in
both free cytosolic and membrane-bound states (Lee et al.
2002). Membrane-bound αS can generate nuclei/oligomers,
which can seed the aggregation of cytosolic αS (Lee et al.
2002). The monomeric αS form in solution has a disordered
structure, whereas the membrane-bound state is rich in
alpha-helix structure (Bodner et al. 2009; Davidson et al.
1998; Eliezer et al. 2001; Fusco et al. 2014). PD pathology
may be associated with change or disruption of αS–lipid
interactions, and in vitro studies have indicated that
early-onset PD mutations can aﬀect the binding of αS to
phospholipids (Choi et al. 2004; Jo et al. 2002; Perrin
et al. 2000). It was suggested that the mechanism of toxicity
in PD involves direct, disruptive interactions between αS
and lipid bilayers involving an interplay between growth
of αS aggregates and lipid extraction (Reynolds et al.
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2011). αS has also been shown to bind speciﬁcally to mito-
chondria, which can lead to disruption of their function
(Nakamura et al. 2008).
Because of the potential relevance to both functional and
pathological roles of αS, further characterization of interac-
tions between αS and lipid membranes is of great impor-
tance. There exists a signiﬁcant body of work aimed at
understanding the nature of interactions between αS and
lipid bilayers but it has proven diﬃcult to characterize
the membrane-bound state and the role of membranes
on αS aggregation. This challenge is directly related to
the diﬃculty in isolating the membrane-bound protein
from brain samples. In vitro studies have also not yet pro-
vided a clear mechanism for αS aggregation in the presence
of lipids in part due to variability of protein-starting sam-
ple and variety of conditions used in kinetic studies of the
conversion of monomeric αS into amyloid ﬁbrils (Cole
et al. 2002; Comellas et al. 2012; Fink, 2006; Galvagnion
et al. 2015, 2016; Grey et al. 2011; Jo et al. 2000; Lee
et al. 2002; Martinez et al. 2007; Zhu & Fink, 2003).
Here we present a biophysical analysis of αS–lipid interac-
tions that unravels a role for the lipid head-group chemis-
try in both αS binding and amyloid formation. Our
experiments led us to the unexpected discovery of a hidden
pathway involving oligomeric αS species that, when bound
to membranes, acted as templates for linear growth of thin
αS amyloid ﬁbrils.
2. Materials and methods
2.1. Materials
DOPS (1,2-dioleoyl-sn-glycero-3-phospho-L-serine, sodium
salt) and DOPG (1,2-dioleoyl-sn-glycero-3-phospho-
(1′-rac-glycerol), sodium salt) chloroform solutions were
purchased from Avanti Polar Lipids (Alabaster, USA).
Sodium phosphate monobasic (NaH2PO4; ⩾99·0%), sodium
phosphate dibasic (Na2HPO4; ⩾99·0%) and thioﬂavin T
UltraPure Grade (ThT) (⩾95%) were purchased from
Sigma-Aldrich (Stockholm, Sweden).
2.2. Protein and lipid vesicle preparation
αS was expressed and puriﬁed as described previously
(Chorell et al. 2015). The protein was stored in a lyophi-
lized form at −80 °C. Monomeric αS was puriﬁed from
the lyophilized powder dissolved in 8 M urea and 20 mM
ethylene diamine tetra-acetic acid by size exclusion chro-
matography (SEC) on a Superdex 75 column (GE
Healthcare, Uppsala, Sweden) into 20 mM phosphate
buﬀer, pH 6·5. Aggregation kinetic studies were also per-
formed with samples of lyophilized protein dissolved
directly in 20 mM phosphate buﬀer, pH 6·5, followed by
ﬁltration through 0·2 µm syringe ﬁlters. These samples
(found to contain both monomers and oligomers)
consisted of only full-length αS (no fragments) as assessed
by SDS–PAGE. The protein concentration was determined
spectrophotometrically using a molar extinction coeﬃcient
of 5960 M−1 cm−1 at 280 nm. Lipid vesicles were prepared
by the lipid ﬁlm hydration method. Appropriate volumes
of chloroform solution of the lipid (DOPS or DOPG)
were transferred to round bottom ﬂask and the organic sol-
vent was removed by rotary evaporation. The resultant ﬁlm
was further dried under vacuum for at least 3 h and then
hydrated with 20 mM phosphate buﬀer, pH 6·5. The
liposome suspensions were extruded through polycarbon-
ate ﬁlters with pore diameters of 100 nm using Avestin
LiposoFast-Basic extruder. The size of the liposomes was
measured by dynamic light scattering using a Zetasizer
Nano ZS instrument (Malvern Instruments Ltd.,
Worcestershire, UK).
2.3. Circular dichroism (CD) spectroscopy
Far-UV CD spectra of 5 µM αS in the presence of increasing
concentrations of liposomes in 20 mM phosphate buﬀer, pH
6·5, were recorded at 37 °C on a Chirascan (Applied
Photophysics, Leatherhead, UK) equipped with a Peltier
temperature control unit. CD spectra between 250 and
200 nm were obtained using quartz cuvettes with path
lengths of 1 mm and the following parameters: a bandwidth
of 1 nm, a step size of 1 nm, a time per point of 1 s and aver-
aging three individual spectra. The CD signal of the buﬀer
and liposomes was recorded and subtracted from the CD
signal of the protein.
2.4. CD data analysis
CD titration curves were ﬁtted using one-step binding
model (Galvagnion et al. 2015): F + LipidL  B(Lipid)L,
where F and B represent αS-free in solution and bound to
the vesicles, respectively, and L is the number of lipid mol-
ecules interacting with one molecule of αS. Then:
KD = [F][LipidL][B(Lipid)L]
(1)
[αS] = [F] + [B] (2)
[Lipid] = L([LipidL] + [B(Lipid)L]) (3)
Detected CD signal can be expressed as a sum of contribu-
tions from αS bound to the vesicles (xB = [B]/[αS])and αS
free in solution (xF = [F]/[αS]):
xB + xF = 1 (4)
CD = xBCDB + xFCDF (5)
where CDB and CDF are the CD signals of the αS bound and
free states, respectively.
From Eqs. (4) and (5):
xB = CD− CDFCDB − CDF (6)

















Matlab software package was used to ﬁt CD titration curves
using Eqs. (6) and (7).
2.5. Aggregation kinetics
αS puriﬁed by SEC just before incubation or αS dissolved
directly in buﬀer was incubated at 37 °C in 20 mM phos-
phate buﬀer, pH 6·5, in the presence of 20 µM thioﬂavin
T (ThT) and diﬀerent concentrations of DOPG and DOPS
liposomes. The samples (60 µl per well) were incubated in
non-binding polystyrene 96-well half-area plates with clear
bottom (Corning Life Sciences, Tewksbury, USA) ThT ﬂuo-
rescence signal was monitored using a microplate reader
(FLUOstar Optima, BMG Labtech, Ortenberg, Germany).
The ﬂuorescence (excitation wavelength 440 nm, emission
wavelength 480 nm) was measured at every 20 min during
the incubation and the plates were agitated for 5 min before
each measurement to assure proper mixing of the samples.
In the absence of liposomes, aggregation of αS does not
occur within the timeframe of our experiments (100 h).
2.6. Atomic force microscopy (AFM)
For AFM imaging, samples were diluted with Milli-Q water
(10–20 times) and deposited on freshly cleaved mica. After
10 min, the mica was rinsed with Milli-Q water and dried
under a gentle nitrogen stream. Images were recorded in
intermittent contact mode in air using an NTEGRA Prima
setup (NT-MDT Spectrum Instruments, Moscow, Russia),
a gold-coated single-crystal silicon cantilever (NT-MDT,
NSG01, spring constant of ∼5·1 N m−1) and a resonance
frequency of ∼180 kHz. 512 pixel images were acquired
with 0·5 Hz scan rate. Images were analyzed using the
WSxM 5·0 software (Horcas et al. 2007).
3. Results
3.1. Binding of αS to anionic lipid vesicles is
modulated by lipid head-group chemistry
We investigated the binding of monomeric αS to lipid ves-
icles composed of DOPS or DOPG lipids by far-UV CD
spectroscopy. Titration of large unilamellar liposomes
(LUVs) to αS induced a change from unordered to alpha-
helix structure in the protein, as indicated by characteristic
negative bands at 208 and 222 nm in the CD spectrum
(Fig. 1a). The CD signal at 222 nm of αS scales almost lin-
early with increasing lipid concentration until saturation is
reached (Fig. 1b) and the data can be well described by a
one-step binding model. Fitting the binding curves with
this model, we estimated the αS–lipid binding stoichiometry
L (how many lipid molecules per one αS molecule) and the
apparent lipid–protein dissociation constant Kd. For both
types of lipid vesicles, the αS dissociation constant was
∼0·1 µM (0·10 ± 0·08 µM for DOPG and 0·14 ± 0·12 µM
for DOPS), while the binding stoichiometry L was approxi-
mately four times higher for DOPS compared with DOPG
vesicles (83 versus 21, respectively, lipids/αS). This result
demonstrates that the binding of αS to negatively charged
lipid vesicles is not solely based on electrostatic forces but
must in part be deﬁned also by interactions between the
hydrophobic face of the amphipathic helix and the mem-
brane interior, which are aﬀected by properties such as sur-
face chemistry and/or local structure of the lipid bilayer
(Perrin et al. 2000).
3.2. Amyloid formation of αS is differentially triggered
by the two kinds of anionic lipid vesicles
Our CD results showed diﬀerent stoichiometry L of αS for
DOPG and DOPS liposomes. To assess the importance of
this for αS amyloid formation in the presence of negatively
charged vesicles, we exploited the typical ThT assay that
utilizes the increase in ﬂuorescence quantum eﬃciency of
ThT when bound to amyloid ﬁbrils (Groenning, 2010;
LeVine, 1993). We chose a ﬁxed concentration of αS (70
µM) and selected the concentrations of lipids according to
the CD titration curves in order to create conditions at
which αS populates both the free in solution and bound to
the vesicle states. In eﬀective terms, this means similar alpha-
helix content of αS but diﬀerent lipid concentrations of
DOPG and DOPS. We also tested saturating conditions at
which essentially all αS molecules are bound to the vesicles.
αS (70 µM) incubated at 37 °C for 100 h did not show an
increase in ThT ﬂuorescence, indicating the absence of amy-
loid ﬁbrils detectable by ThT (Fig. 2). AFM conﬁrmed the
lack of amyloid ﬁbrils at this condition. In contrast, the
presence of negatively charged DOPG vesicles at lipid/pro-
tein molar ratios of 2·1 (10% αS bound to vesicles), 4·2
(20% αS bound) and 11·2 (55% αS bound) triggered the for-
mation of amyloid ﬁbrils by αS (Figs 2a and 2c). At higher
DOPG/αS molar ratios (⩾22·4), where all αS were bound to
the vesicles, no increase in ThT ﬂuorescence was observed.
DOPS vesicles also promoted aggregation of αS but with dif-
ferent features. At a DOPS/αS ratio of 10·5 (13% αS bound),
protein aggregation was detected, but at higher ratios of
DOPS/αS (i.e., 21 and 56) no ThT ﬂuorescence was
observed albeit, according to the CD titration, both free
and bound αS states should be present (Figs 2b and 2d).
AFM imaging of end point samples (after 100 h) indicated
that in the plateau region of ThT ﬂuorescence, the ﬁbrils
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Fig. 1. Secondary structure of αS in the presence of lipid vesicles. (a) CD spectra of 5 µM αS alone (red) and 5 µM αS in the presence
of 200 µM of DOPG (black) and 200 µM (dashed green) and 530 µM (yellow) of DOPS. (b) Mean residue ellipticity at 222 nm upon titra-
tion of DOPG (black, circles) and DOPS (yellow, squares) vesicles into 5 µM αS solution; the experimental data are shown as symbols
and a one-step binding model ﬁt is shown as solid lines.
Fig. 2. Aggregation of αS in the presence of negatively charged vesicles. ThT ﬂuorescence of αS alone (black) (a, b) and of αS incubated
in the presence of 150 µM (10% αS bound, blue), 300 µM (20%, red) and 790 µM (55%, yellow) of DOPG (a) or in the presence of 735
µM (13%, blue), 1470 µM (25%, red) and 3920 µM (67%, yellow) of DOPS (b). Boxplots comparing ThT intensity at plateau (t = 90 h) of
αS incubated in the presence of DOPG vesicles (c) and DOPS vesicles (d). AFM images of αS amyloid ﬁbrils at the end point of the
aggregation experiment after incubation of monomeric αS in the presence of 300 µM DOPG (e) and 735 µM DOPS (f) vesicles. Scale
bars 500 nm; height color-scale is shown on the right.
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formed in the presence of both types of negatively charged
vesicles were heterogeneous, with some ﬁbers of dimensions
of 7–9 nm in height as well as some with dimensions <5 nm
in height (Figs 2e and 2f). For comparison, these amyloid
ﬁber properties are in agreement with those of αS amyloids
formed in the absence of vesicles but in the presence of a
small glass bead and agitation to speed up the reaction
(Fig. S1).
3.3. αS oligomer ‘contamination’ dramatically alters
αS aggregation in the presence of negatively charged
vesicles
In the above experiments, stock lyophilized αS was dissolved
and puriﬁed by SEC prior to use as a standard step to always
assure monomeric starting material. Indeed, SEC analysis of
lyophilized αS samples showed the presence of protein spe-
cies with a larger apparent size, indicative of an assembled
and oligomeric fraction (Fig. S2). Moreover, AFM analysis
demonstrated the presence of spherical structures with
heights in the range of 1–3 nm in the lyophilized αS sample
(Fig. S2). Based on the SEC analysis, the oligomer fraction
corresponds to approximately 5% of total protein and the
oligomer size appears to be about 80 kDa (Fig. S2). The
oligomers appeared stable as they could not be dissociated
by 8 M urea (Fig. S2). As expected for a sample containing
mostly monomers in mixture with a small fraction of oligo-
mers, CD titrations curves with negatively charged vesicles
using this αS source matched the data collected for
monomer-only αS (Fig. S3, cf. Fig. 1).
Lyophilization has been reported to induce the formation of
αS oligomers and it has been proposed that these species
may aﬀect αS aggregation (Fredenburg et al. 2007; Lashuel
et al. 2002; Volles & Lansbury, 2002). Therefore, we also
investigated the aggregation kinetics of the heterogeneous
αS preparation (i.e., lyophilized αS dissolved without further
puriﬁcation) in the presence of negatively charged vesicles.
The ThT signal of lyophilized αS reconstituted in buﬀer
without vesicles did not change within 100 h at aggregation
conditions, indicating no amyloid formation and, impor-
tantly, is the same result as that for the monomer-only αS
sample in the absence of vesicles (Figs 3a and 3b).
In contrast, for this αS sample, the ThT signal increased
almost linearly with time without lag time in the presence
of DOPG LUVs at lipid/protein ratios of 2·1, 4·2, 11·2 and
DOPS/protein ratios of 10·5 (Figs 3a and 3b). The ampli-
tudes of these ThT changes were however very low, but
nonetheless clearly distinct from the ﬂat ThT curves for
αS without vesicles. AFM analysis revealed that thin amy-
loid ﬁbrils, 3–4 nm in height, were present in these samples
after the reactions (Figs 3c and 3d). Thus, if a small fraction
of oligomers is present along with αS monomers, together
with negatively charged vesicles, elongation of a small num-
ber of ﬁbrils takes place, most likely with the pre-formed
‘contaminating’ oligomers as starting nuclei. At the same
time, and most surprisingly, the typical cooperative aggrega-
tion seen for the monomer-only αS samples in the presence
of vesicles (Fig. 2) is absent.
4. Discussion
The binding of αS to lipid membranes is described to
depend on numerous factors such as solution conditions,
chemical properties of the lipids, lipid bilayer phase state
and membrane curvature (Galvagnion et al. 2016; Middle-
ton & Rhoades, 2010; Ouberai et al. 2013; Shvadchak
et al. 2011a, b). Under the experimental conditions of this
study, induction of the same amount of alpha-helical con-
tent in αS required four times higher concentration of
DOPS than DOPG vesicles. The area per lipid molecule of
DOPS (65·3 Å2 (Petrache et al. 2004)) is almost 10% smaller
than that of DOPG (70·8 Å2 (Pan et al. 2012)), indicating
that attractive interactions between PS head-group are
stronger than between PG head-group. Stronger attractive
interactions will result in higher molecular order in the
polar head-group region of DOPS relative to DOPG lipid
layers (Lindblom et al. 1991) and increased exposure of
hydrophobic parts of DOPG relative to DOPS lipid bilayers.
It has been previously described that αS binds with higher
aﬃnity to model membranes with defects, indicating that
lipid packing strongly aﬀects αS–membrane interactions
(Nuscher et al. 2004; Ouberai et al. 2013; Shvadchak et al.
2011a). Thus, DOPG may expose more hydrophobic areas
and αS may insert deeper into the DOPG membrane than
the DOPS membrane. This will increase the eﬀective area
of binding, since when the bilayer expands, the eﬀective sur-
face area per lipid will increase. This reasoning may explain
the lower number of lipid molecules per αS molecule for
DOPG compared with DOPS. Diﬀerent reported aﬃnities
of αS for negatively charged head-group, going beyond the
total charge, also emphasize speciﬁcity of αS among acidic
phospholipids (Nakamura et al. 2008; Rhoades et al. 2006).
CD of αS binding to anionic lipid vesicles shows a transition
from mostly disordered to largely alpha-helical conforma-
tion of αS. At an excess of lipids, most of αS monomers
are bound to the vesicles. We observed a maximum value
of mean residue ellipticity (MRE) at 222 nm of −25 × 103
and −27 × 103 deg m−1 M−1 for αS bound to the DOPG
and DOPS vesicles, respectively. Using the MRE values
and assuming that all αS molecules are bound to the vesi-
cles, we estimate that 68–74% of the protein is in alpha-
helical structure (Scholtz et al. 1991), which corresponds
to ∼100 out of the 140 residues of αS. This result agrees
with structural studies that have shown that the ﬁrst 100
N-terminal residues of αS interact with lipid vesicles
(Bodner et al. 2009, 2010). The number of αS residues
bound to the vesicles can be estimated by assuming that
the dimensions of the alpha-helix are ∼0·13 nm per residue
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in length (Lee et al. 2004) and 1 nm in width in combina-
tion with the lipid-to-protein ratio at saturation determined
here of 21 (lipid area of 7·5 nm2) for DOPG vesicles and 83
(lipid area of 27 nm2) for DOPS. We arrive at the result that
only about 58 residues of each αS can be accommodated on
DOPG vesicles at saturation, whereas on DOPS surfaces the
available area per αS monomer corresponds to that of 200
residues in alpha-helical conformation.
This simple analysis may suggest that αS induces a rear-
rangement of the DOPG bilayer resulting in lateral expan-
sion such that accommodation of 100 αS residues per
molecule is possible. In accord, it has been proposed that
αS binding to lipid bilayers can involve insertion of helical
segments in the head-group region resulting in lateral
expansion; importantly, this eﬀect was highly dependent
on the degree of order in the membrane (Ouberai et al.
2013). Another possibility is that part of the αS helix is pro-
truding from the membrane surface of the DOPG vesicles. It
was previously reported that binding of αS to PS-containing
vesicles requires all residues 1–102, whereas the binding to
phosphatidic acid containing vesicles can be mediated by
just one of the sequence segments 1–42, 43–56 or 56–102
(Perrin et al. 2000).
We observed that DOPG and DOPS vesicles modulate dif-
ferently amyloid formation of monomeric αS. At lipid/pro-
tein ratios high enough to have all αS molecules bound to
the vesicles, the protein did not aggregate within the time
frame of our experiments (100 h). However, for both vesicle
types, when free monomers are present in solution, ﬁbril
formation took place and the process showed an initial lag
phase, which is attributed to a nucleation-dependent mech-
anism (Fink, 2006; Wood et al. 1999). As the nucleation of
αS occurred faster in the presence of DOPG vesicles than in
their absence, we can assume that it is the lipid-bound αS
fraction that forms the initial nuclei. Probably, the lipid
environment increases the local concentration of αS, pro-
moting self-assembly of membrane-bound αS molecules
and consequently leading to the formation of nuclei on
the bilayer surface. If we make the assumption that alpha-
helix content corresponds to bound αS, then DOPG vesicles
induce amyloid formation of monomeric αS as long as both
bound and free protein states are present. In contrast, in the
case of DOPS, aggregation of αS occurred only for 13% of
αS bound to lipids and the lag phase with DOPS was longer
than for αS with DOPG at the same percentage of vesicle-
bound protein. Higher DOPS-bound fraction of αS than
13% resulted in the absence of any amyloid formation.
Also when comparing the DOPS and DOPG results for
similar absolute lipid concentrations, corresponding to
lipid/protein ratio of 10·5 and 11·2, respectively, the lag
times of αS amyloid formation are still much longer in
the case of DOPS than DOPG. These data suggest that eﬃ-
ciency of αS nucleation on vesicles is dependent on vesicle
surface chemistry, dynamics and structure, which together
deﬁne the αS binding mode. It was previously suggested
Fig. 3. Aggregation of αS, consisting of monomers and a small fraction of oligomers, in the presence of negatively charged vesicles. ThT
ﬂuorescence of αS alone (black) (a, b) and of αS incubated in the presence of 150 µM (blue), 300 µM (red), 790 µM (yellow) of DOPG
vesicles (a) or in the presence of 735 µM (blue), 1470 µM (red) and 3920 µM (yellow) of DOPS vesicles (b). We note that the ThT inten-
sity in these graphs are approximately 20-fold lower than in Figs 2a and 2b. AFM images of αS amyloid ﬁbrils at the end point of the
aggregation experiment after incubation in the presence of 300 µM DOPG (c) and 735 µM DOPS (d) vesicles. Scale bars 500 nm; height
color-scale is shown on the right.
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that αS aggregation is promoted only by lipids with short
saturated hydrocarbon chains (12 or 14 carbon chain)
(Galvagnion et al. 2016). Our results here show that αS
aggregation can also be promoted by long unsaturated
hydrocarbon chains (i.e., DOPS, DOPG; 18 carbon chain
with one double bond) at some conditions. Based on previ-
ous studies, it is possible that αS aggregation on vesicles
involves extraction of lipids from the bilayer and partial pro-
tein–lipid co-aggregation (Hellstrand et al. 2013; Reynolds
et al. 2011).
Unexpectedly, we found that αS amyloid formation in the
presence of vesicles changes dramatically when a small frac-
tion of oligomers is present. The AFM data suggested the
formation of a small fraction of amyloid ﬁbrils that were
thin (Fink, 2006; Khurana et al. 2003). These amyloid ﬁbrils
grew without lag phase implying that the pre-formed ‘con-
taminating’ oligomers were the source of nuclei. Notably,
this process blocked the aggregation of the remaining
monomers, which contrasts the result for monomers-only
αS samples in the presence of negatively charged vesicles.
Since amyloid ﬁbrils were absent from aggregation reactions
of this αS sample without vesicles, the ‘contaminating’ olig-
omers must depend on the vesicles for nucleation of amy-
loid formation. αS oligomers are described to interact with
negatively charged bilayers and may cause membrane dis-
ruption (Fredenburg et al. 2007; van Rooijen et al. 2009).
The molecular details of oligomer–membrane interactions
and the eﬀect on surrounding monomeric species by those
interactions are still unclear. If αS interactions with lipid
vesicles are cooperative, then even a few (or one) oligomers
may alter the way many monomers arrange on the surface
of the liposome. Notably, a study on αS aggregation on sup-
ported lipid bilayers showed that monomeric αS has a
higher aﬃnity for protein aggregates on the surface than
for the lipid bilayer itself (Reynolds et al. 2011). Moreover,
similar to our results here, the study showed that after the
initial formation of the ﬁrst aggregates, these grew with
time but the formation of new αS seeds occurs at much
lower frequency.
Our ﬁndings point out the importance of careful assessment
of membrane properties, and synergistic eﬀects due to pro-
tein–lipid interactions, as well as both lipid vesicle and pro-
tein structural dynamics. Our study also highlights the
importance of protein preparation procedures. The litera-
ture around αS aggregation includes a wide variation of
results and at least some of these may be explained by dif-
ferences in protein starting material.
4.1. Speculation box
Based on this work, we speculate that consequences of αS
interactions with synaptic vesicles and membranes in vivo
will depend on simultaneous interactions with other pro-
teins that may modulate vesicle surface properties. It
appears that binding of pre-formed oligomers to vesicles
alters surface properties such that monomers are restricted
from independent formation of amyloid seeds. Our results
also highlight the question of what in vitro conditions are
most relevant for the in vivo scenario that ultimately
results in PD. Finally, we note that to gain real biological
bearing of these in vitro ﬁndings, vesicles composed of
mixed lipids mimicking those in neuronal cells should
be investigated.
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